Please assess the completion status of the following clinical trial:

Trial Title: TraStuzumAb-Radiotherapy : Impact on the Cerebral Prevention

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with breast cancer, expressing HER2-NEU (score +++ in ICH or ++ and amplification on FISH or CISH, SISH)~* Visceral metastasis, only or multiple~* First line metastasis treatment by Trastuzumab in association with chemotherapy~* Good general conditions: OMS=\<2 or Karnofsky \>=70%~* Age \> 18 years and \< 70 years~* Life expectancy \>=3 mois~* No Trastuzumab since more of 6 months~* No cerebral metastasis (MRI)~* Efficacy contraception for women with genital capacities~* Consent signed by the patient~Exclusion Criteria~* Contraindication to IRM~* Psychiatric decease~* Prior cerebral radiotherapy,~* Geographical constraint, compromising the fallow of patients~* Infectious or other serious pathology, likely to stop the treatment~* Positive serology (HIV, hBC, hBS)~* Inclusion in an other clinical trial or in the 4 weeks before th inclusion~* Pregnant or breastfeeding women

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Arm A (Type: ACTIVE_COMPARATOR): Without cerebral prophylactic radiation
- Arm B (Type: EXPERIMENTAL): With cerebral prophylactic radiation

Based on this trial design, predict the completion outcome and termination type (if applicable).